Actitest and Fibrotest Profile, Serum

Actitest and Fibrotest Overview

Fibrosis is a gradual build-up of scar tissue, which can lead to liver damage. The Actitest and Fibrotest are non-invasive laboratory tests used to assess liver fibrosis and inflammation. These tests provide a quantitative evaluation of liver fibrosis and inflammation scores, offering an alternative to liver biopsy for assessing liver disease severity. The Actitest measures several markers of liver function and injury, including SGPT (alanine aminotransferase), bilirubin, GGTP (gamma-glutamyl transferase), alpha2 macroglobulin, apo A1 (apolipoprotein A1), and haptoglobulin. These markers reflect various aspects of liver health and can indicate liver inflammation and damage. The Fibrotest measures several serum markers, including alpha2 macroglobulin, apo A1, haptoglobulin, bilirubin, and gamma globulin, to assess liver fibrosis. These markers are combined with patient age and gender to calculate a Fibrotest score. Both the Actitest and Fibrotest results are interpreted in the context of a statistical analysis and comparison to reference values. The scores obtained from these tests are then used to determine the degree of liver fibrosis and inflammation. To facilitate the interpretation of these results, the scores are often presented graphically.

The Actitest and Fibrotest are non-invasive laboratory tests that provide a comprehensive assessment of liver health by evaluating the extent of fibrosis and inflammation in the liver. These tests serve as an alternative to liver biopsy, offering a less invasive means of determining the severity of liver disease. By measuring specific serum biomarkers, the Fibrotest assesses liver fibrosis, while the Actitest incorporates an additional marker to evaluate inflammatory activity.

The Actitest and Fibrotest are valuable tools for doctors in diagnosing and monitoring liver diseases, such as hepatitis B or C, and assessing the progression of liver fibrosis. These tests aid in determining the effectiveness of treatment for liver disease and assessing the risk of developing end-stage liver disease.